semaglutide non responder GLP-1 nonresponders: Up to 1 in 5 people don't lose weight Semaglutide Modulates Extracellular Matrix Production

GLP-1s are also being tested in diseases ranging from Parkinsons disease to a range of compulsive or addictive behaviors

This current study involved people with type two diabetes who received weight-loss medication

Across both trials, adverse events such as nausea, diarrhea, and vomiting were more common among the group who received the higher dose, with most of the patients seeing these symptoms resolved before the end of the trial

The convergence of sensory science with precision medicine holds particular promise for developing more effective, targeted interventions for metabolic diseases, where optimizing taste perception could significantly improve dietary adherence and treatment outcomes while minimizing side effects